Defective IL-4 signaling in T cells defines severe common variable immunodeficiency

Area of Science:

• Immunology
• Cellular Biology
• Clinical Medicine

Background:

• Common variable immunodeficiency (CVID) is characterized by hypogammaglobulinemia and B-cell dysfunction, leading to heterogeneous clinical presentations.
• Severe non-infectious complications, including autoimmunity and granulomatous disease, significantly impact CVID patient morbidity.
• T-cell abnormalities are implicated in CVID pathogenesis, but specific functional T-cell characteristics linked to clinical subtypes remain unclear.

Purpose of the Study:

• To investigate functional T-cell signaling pathways in response to common gamma-chain cytokines in CVID patients.
• To correlate T-cell signaling defects with specific clinical subtypes of CVID, particularly severe non-infectious complications.
• To elucidate the molecular mechanisms underlying potential T-cell dysfunction in CVID.

Main Methods:

• Analysis of peripheral blood T cells from 29 CVID patients and 19 healthy donors.
• Assessment of cytokine-induced phosphorylation of STAT3, STAT5, and STAT6 in response to IL-2, IL-4, IL-7, and IL-21.
• Evaluation of T-helper (Th)1/Th2 polarization and expression of IL-4 receptor and downstream signaling molecules.

Main Results:

• A subgroup of 7 CVID patients exhibited impaired IL-4-induced p-STAT6 signaling in naive and memory CD4 and CD8 T cells.
• This IL-4 signaling defect correlated with the highest burden of severe non-infectious complications and persisted over time.
• Lower mRNA levels of IL-4Rα and JAK1 were observed in these patients, suggesting a molecular basis for the impaired IL-4 signaling and a Th1 bias.

Conclusions:

• Identified a distinct subgroup of CVID patients with defective IL-4 signaling in T cells.
• This signaling defect is associated with severe clinical manifestations, including inflammation and autoimmunity.
• The findings highlight the role of IL-4 signaling pathways in CVID pathogenesis and suggest potential therapeutic targets.